SynCardia is the sole provider of the world’s only heart replacement technology with commercial approval in the U.S., Canada and Europe. By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and mechanical circulatory support (MCS) programs around the world, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement.
When a donor heart isn’t available, or isn’t an option, the SynCardia temporary Total Artificial Heart (TAH) can offer patients with end-stage biventricular failure the gift of more time—more time with their families and friends, more time outside the hospital enjoying life and more time to receive a heart transplant.
The world’s first and only commercially approved Total Artificial Heart, the 70cc TAH has been implanted in more than 1,700 patients worldwide and accounts for more than 600 patient-years of support.
A smaller version of the 70cc TAH, the 50cc TAH is designed to fit patients of smaller stature, allowing more women and adolescents to access this novel technology. The 50cc TAH has been implanted in more than 60 patients worldwide.
The state-of-the-art C2 Driver provides pneumatic power to the TAH from implant through patient recovery in the hospital.
A smaller, portable pneumatic pump for the TAH, the Freedom Driver increases mobility and allows stable patients who meet discharge criteria to enjoy life at home while they wait for a matching donor heart.